OTC · Health care

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

It posted a net loss of $13M. At June 30, 2026 it held $19.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.

Watch RVPH in 60 seconds

Price

$0.48

-7.69% on the day · September 25, 2026

52-week range $0.26 to $17.20

Market cap

$6.3M

What Reviva Pharmaceuticals Holdings, Inc. does

Reviva Pharmaceuticals Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker RVPH.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$20.2M	-$19.9M	-$5.48	n/a
2024	n/a	-$30.8M	-$29.9M	-$17.73	n/a
2023	n/a	-$39.5M	-$39.3M	-$32.51	n/a
2022	n/a	-$28.2M	-$28.3M	-$28.57	n/a
2021	n/a	-$10.1M	-$8.5M	-$13.25	n/a
2021	n/a	-$10.1M	-$8.5M	-$13.25	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 11, 2026.

Estimated from its filing rhythm: about 91 days after its last report of August 12, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What Reviva Pharmaceuticals Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 12, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.19 versus -$2.40.
August 12, 2026
Quarterly results 8-K
August 3, 2026
Passive stake changed SCHEDULE 13G/A
July 10, 2026
Delisting notice 25-NSE
May 15, 2026
Passive stake changed SCHEDULE 13G/A
May 14, 2026
Passive stake (5% or more) SCHEDULE 13G
May 13, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.46 versus -$2.61.
May 13, 2026
Quarterly results 8-K
May 13, 2026
Stock exchange listing notice 8-K
April 15, 2026
Investor disclosure 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on March 20, 2026. Insider transactions on SEC

Insider trades

What the people running Reviva Pharmaceuticals Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns RVPH

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Integrated Core Strategies (US) LLC13G, passive with 3 related filers	8.2%	1,072,690	August 3, 2026

Latest filings below 5%: CVI Investments, Inc. 4.9% (May 15, 2026); Parag Saxena 2.8% (March 24, 2026); 683 Capital Management, LLC 3% (February 17, 2026); Bhat Laxminarayan 3.8% (September 24, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about RVPH

What does Reviva Pharmaceuticals Holdings, Inc. do?

Reviva Pharmaceuticals Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker RVPH.

Is Reviva Pharmaceuticals Holdings, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $13M.

When did Reviva Pharmaceuticals Holdings, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare RVPH with

Compare RVPH with any company

Follow RVPH

Get an email when Reviva Pharmaceuticals Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow RVPH: get an email when it files

Where the numbers come from

Financial figures are the values Reviva Pharmaceuticals Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.